MedTrace Logo

Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia

NCT03999190 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-05-29

No results posted yet for this study

Summary

The goals of this study is to determine (1) if differences in D2/3 receptor affinity states exist between medication-free subjects with SCH (MF-S) compared with healthy controls (HC), (2) the degree to which pre- and post-synaptic factors contribute to increased striatal dopamine (DA) signaling in MF-S and (3) to test the hypotheses that optimal DA transmission in the dorsal caudate (DCA) is necessary for normal working memory (WM) function.

Conditions

Interventions

DRUG

NPA radiotracer

\[11C\]NPA radiotracer, 2 injection per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).

DRUG

Raclopride radiotracer

\[11C\]raclopride radiotracer, 2 injections per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).

DRUG

Dextroamphetamine

Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).

Sponsors & Collaborators

Principal Investigators

  • William Frankle · New York Langone Health

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03999190 on ClinicalTrials.gov